Lipid metabolic reprogramming in cancer cells

Many human diseases, including metabolic, immune and central nervous system disorders, as well as cancer, are the consequence of an alteration in lipid metabolic enzymes and their pathways. This illustrates the fundamental role played by lipids in maintaining membrane homeostasis and normal function...

Full description

Saved in:
Bibliographic Details
Published in:Oncogenesis (New York, NY) Vol. 5; no. 1; p. e189
Main Authors: Beloribi-Djefaflia, S, Vasseur, S, Guillaumond, F
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 25.01.2016
Nature Publishing Group
Nature Publishing Group: Open Access Journals - Option C
Subjects:
101/58
631/67/1059/602
631/67/2327
64/110
Apoptosis
Cancer
Cell Biology
Cellular biology
Enzymes
Human Genetics
Internal Medicine
Life Sciences
Lipids
Medicine
Medicine & Public Health
Metabolism
Oncology
Review
Targeted therapies
Cancer metabolism
ISSN:2157-9024, 2157-9024
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Many human diseases, including metabolic, immune and central nervous system disorders, as well as cancer, are the consequence of an alteration in lipid metabolic enzymes and their pathways. This illustrates the fundamental role played by lipids in maintaining membrane homeostasis and normal function in healthy cells. We reviewed the major lipid dysfunctions occurring during tumor development, as determined using systems biology approaches. In it, we provide detailed insight into the essential roles exerted by specific lipids in mediating intracellular oncogenic signaling, endoplasmic reticulum stress and bidirectional crosstalk between cells of the tumor microenvironment and cancer cells. Finally, we summarize the advances in ongoing research aimed at exploiting the dependency of cancer cells on lipids to abolish tumor progression.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2157-9024
2157-9024
DOI:10.1038/oncsis.2015.49